Doctor of Dentistry Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Vahik Meserkhani

Dentist, Prosthodontics Glendale, CA Doctor of Dentistry

NPI 1275784183 CMS profile 58537

520 E Broadway, Llu School Of Dentistry, Glendale, CA 91205

Open in the dashboard

General payments

$234,516

350 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Vahik Meserkhani of Glendale, CA is reported in the CMS Open Payments database as having received $234,516 across 350 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Dentist, Prosthodontics profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $44,229 28
2024 General $40,598 55
2023 General $32,346 52
2022 General $47,382 79
2021 General $9,724 31
2020 General $14,074 16
2019 General $46,163 89

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Vahik Meserkhani
  • Dentist, Prosthodontics median
  • Middle half of Dentist, Prosthodontics
  • National median

In program year 2025, general payments to Vahik Meserkhani were reported at $44,229. Among 1,396 Dentist, Prosthodontics profiles paid that year, the median was $118 and the middle half received between $44 and $351.

Show as a table
Year Vahik Meserkhani Dentist, Prosthodontics median Middle half National median
2019 $46,163 $107 $36–$389 $163
2020 $14,074 $100 $41–$311 $114
2021 $9,724 $129 $40–$398 $132
2022 $47,382 $129 $47–$460 $149
2023 $32,346 $135 $44–$432 $160
2024 $40,598 $142 $45–$420 $164
2025 $44,229 $118 $44–$351 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Zimvie Inc. $163,367 196 payments
  2. Zimmer Biomet Holdings, Inc. $69,258 108 payments
  3. Straumann USA LLC $853 14 payments
  4. Implant Direct Sybron International LLC $642 17 payments
  5. Geistlich Pharma, North America, Inc. $138 4 payments
  6. Nobel Biocare USA $62 1 payment
  7. Kulzer, LLC $50 3 payments
  8. 3M Company $50 2 payments
  9. Philips Electronics North America Corporation $35 2 payments
  10. BioHorizons Implant Systems Inc. $24 1 payment
  11. Other $35 2 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $194,050 103 payments
  2. Travel and Lodging $20,792 51 payments
  3. Compensation for serving as faculty or as a speaker for a medical education program $10,500 1 payment
  4. Food and Beverage $9,163 194 payments
  5. Entertainment $12 1 payment
Products named General payments · program years 2019–2025
  1. Tapered Screw-Vent $72,460 67 payments
  2. Zimmer Biomet Instruments and Implants $49,993 31 payments
  3. OSSEOTITE NT $20,232 17 payments
  4. Diem2-RevitaliZe $20,200 13 payments
  5. TSX Implants $11,051 19 payments
  6. 3i T3 $8,435 9 payments
  7. All T3 Implants Dental $6,821 6 payments
  8. All T3 Implants Dental $5,063 9 payments
  9. RealGUIDE IMPLANT MOUNT $4,389 7 payments
  10. Bellatek $3,440 3 payments
  11. Other $8,644 101 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

67

Median for Maxillofacial Surgery: 343

Drug cost

$236

Median for Maxillofacial Surgery: $1,437

Branded share of claims

35.8%

Median for Maxillofacial Surgery: 21.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 24 $140
Amoxicillin Generic 31 $72
Ibuprofen Generic 12 $25

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 692 Part D prescribers listed as Maxillofacial Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 19 billing codes

Paid by Medicare

$104,316

Medicare's payments for the services billed

Medicare patients

70

Average age 74

Services billed

238

44 women, 26 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 74%
Ischemic heart disease 49%
Diabetes 47%
Depression 39%
Osteoporosis 31%
Alzheimer's or dementia 26%
Heart failure 19%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

350 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dentist, Prosthodontics in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record